Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Colorectal cancer is the fifth leading cause of cancer death worldwide [1] . Worldwide, colorectal cancer accounted for approximately 1.2 million new cancer cases in 2008 [2, 3] . Surgical resection is the only curative treatment for locoregional disease, but 40–50% of patients have recurrences and or metastasis and die of metastatic disease [4] . The benefits of 5-fluorouracil (5-FU)-based adjuvant chemotherapy in reducing recurrence and prolonging survival are well established, especially for stage III disease, and this has become the standard of care worldwide [5–10] …